In recent trading session, ReShape Lifesciences Inc (NASDAQ:RSLS) saw 0.38 million shares changing hands at last check today with its beta currently measuring 1.44. Company’s recent per share price level of $1.19 trading at -$0.04 or -3.25% at last check today assigns it a market valuation of $0.87M. That most recent trading price of RSLS’s stock is at a discount of -2336.97% from its 52-week high price of $29.00 and is indicating a premium of 15.13% from its 52-week low price of $1.01.

For ReShape Lifesciences Inc (RSLS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.

ReShape Lifesciences Inc (NASDAQ:RSLS) trade information

Upright in the red during last session for losing -3.25%, in the last five days RSLS remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.19 price level, adding 54.0% to its value on the day. ReShape Lifesciences Inc’s shares saw a change of -73.32% in year-to-date performance and have moved -53.15% in past 5-day. ReShape Lifesciences Inc (NASDAQ:RSLS) showed a performance of -72.39% in past 30-days.

On the other hand, Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.42 shares of worth $2804.0 or 0.33% of the total outstanding shares. The later fund manager was in possession of 860.0 shares on Sep 30, 2024, making its stake of worth around $997.0 in the company or a holder of 0.12% of company’s stock.